Cambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long, interactive festival with Oxford and London for the very first time. The Cambridge-Oxford-London corridor is widely regarded as one of the most productive life sciences clusters in the world, home to hundreds of biotechnology companies, globally recognised research institutions and a rapidly expanding venture capital ecosystem. Building on last year’s event, which attracted more than 4,000 attendees across 25+ venues and 200+ sessions, CWOW 2026 will convene investors,…
by Alicia Gailliez, Business Development Manager, One Nucleus
Breakthroughs are accelerating across therapeutics, data platforms, regulatory systems and business models. Yet challenges remain in how we develop and scale innovation within an increasingly complex landscape. Addressing these challenges requires collaboration across the life science ecosystem.
ON Helix brings together this breadth and diversity, connecting biotech innovators, pharma, academia, service providers and investors to create an environment for meaningful peer-to-peer learning and deal-making. It is through these…
by Alicia Gailliez, Business Development Manager, One Nucleus
The winners of the Boston Bootcamp 2026 have been announced! Congratulations to ExpressionEdits, Monument Therapeutics, Profionics, and Stick Therapeutics. These four standout companies impressed a panel of esteemed UK and US judges during the online presentation session on 24 February, where 16 companies each pitched their vision in a 5-minute slot.
With the competition now moving ever closer towards the Boston visit (27–30 April), the focus shifts to preparatory sessions with Bootcamp supporters and sponsors. These sessions are…
Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform
Cambridge, UK, 31 March 2026: Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP). The fundraise was led by Parkwalk, and joined by The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, and Start Codon. The investment will facilitate commercial…
Rebrand follows appointment of new leadership as company drives commercialization of INDUCE-seq® platform to address regulatory gaps in off-target reporting for gene editing programs
Cambridge, UK, 31 March 2026 – Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today introduced new branding and comprehensive website as part of its strategic repositioning. At a time where the gene editing industry is facing increasing regulatory demands for genome-wide off-target data, the update has…
In this episode, host Sonjoy Brahma, VP of Clinical Operations at tranScrip, is joined by Joab Williamson of Faron Pharmaceuticals to explore the operational realities of working within small emerging biotech companies. They discuss the challenges of rare oncology development, how cash runway and clinical milestones shape strategy, and why flexibility, external expertise and careful planning are essential to balanced decision-making. Together, they share practical insights into managing risk, controlling costs and advancing clinical programmes with confidence in a resource-constrained…
Sandwich, UK — 25 March 2026: Discovery Park, Kent’s science and innovation hub, has launched the sixth edition of its Discovery Spark accelerator programme, welcoming 11 startups to its campus in Sandwich.
The business growth programme has already supported 50 companies and 76 founders, with alumni securing £5.5m in UKRI funding since launching in 2023. For Cohort 6.0, the startups were selected based on the need for their innovation, the uniqueness of their solution, and the strength of their team. Spark is designed to provide opportunities for companies to grow a network of peers,…
Amsbio announce the RPMotion – a spinning organoid bioreactor that facilitates fast, easy and efficient organoid culture for drug discovery, disease modelling and regenerative medicine.
Until now organoid expansion has been an expensive and time-consuming static process, requiring large amounts of materials, skilled labour and time. Benefiting from a novel bioreactor design – the RPMotion – overcomes current limitations in organoid expansion / differentiation methodologies, helping laboratories improve efficiency and reduce reliance on manual processes.…
LONDON, UK, March 18, 2026 / Biotech Newswire / -- Touchlight, in collaboration with New England Biolabs (NEB®), announces the launch of the EnClose™ Cell-free dbDNA™ Synthesis Kit, a new benchtop solution enabling rapid enzymatic production of Touchlight’s proprietary doggybone DNA™ (dbDNA™). This linear, covalently closed, double-stranded DNA format offers researchers a fast, cell-free alternative to traditional plasmid DNA, supporting the growing demand for nucleic acid therapeutics.
Traditional plasmid manufacturing remains a critical bottleneck for advanced therapy developers, often…
Senior figures from across industry, academia, investment and government met yesterday (Thursday 26 March 2026) at the House of Lords, for a roundtable hosted by The Lord Ranger of Northwood, to discuss the findings of a new report commissioned by Pioneer Group and The Crown Estate, and authored by Henham Strategy.
The new report Beyond the Capital Gap: How do we develop an operational blueprint to capitalise on UK science, shares findings from the second phase of Pioneer Group’s landmark research report examining how the UK can better convert its world leading science into globally…